Nintx develops next-generation pharmaceutical and nutraceutical therapies by translating complex intra- and interspecies biological interactions into novel treatments. The company leverages proprietary omics and data analytics technologies to discover natural product ingredients that modulate human biological targets and the gut microbiome. This platform focuses on creating multi-target solutions for multifactorial diseases linked to human biology and microbial crosstalk.
Funding
$13M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery methods often focus on single targets, which may not effectively address multifactorial diseases involving complex biological interactions. Identifying and developing therapies that can modulate multiple targets and the microbiome simultaneously remains a significant challenge.
Solution
Nintx leverages Brazil's biodiversity and advanced technologies to develop plant-based, multi-target therapies for multifactorial diseases. The company utilizes its proprietary xGIbiomics platform, which simulates the human gastrointestinal system and microbiome, to understand complex biological interactions. Nintx's GAIApath, an AI-driven analytics platform, maps and selects medicinal plants with the ability to modulate multiple targets and the microbiome. Through partnerships and innovative research programs, Nintx aims to translate complex biological interactions into novel therapies.
Target Audience
Nintx's target audience includes pharmaceutical companies, research institutions, and healthcare providers focused on developing and utilizing therapies for multifactorial diseases.
Features
- xGIbiomics: A proprietary platform that emulates the human gastrointestinal digestive system and microbiome for drug discovery.
- GAIApath: An AI and analytics solution to map and select medicinal plants with the ability to modulate targets and the microbiome.
- Bioprospection: Partnership with CNPEM (Brazilian Center for Research in Energy and Materials) to exponentialize natural products from the Brazilian biodiversity.
- Ethnopharmacology: Partnerships with ADESTE and CIEnP to develop multi-target therapies based on medicinal plants.
- Focus on multi-target therapies: Addressing the limitations of traditional single-target drug approaches.